Last reviewed · How we verify
Aliskiren and HCTZ
Aliskiren and HCTZ is a Small molecule drug developed by Novartis. It is currently FDA-approved.
Aliskiren and HCTZ, marketed by Novartis, is a combination therapy currently available in the hypertension market. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports current market positioning. The primary risk is the potential increase in generic competition following the patent expiry, which could erode market share and revenue.
At a glance
| Generic name | Aliskiren and HCTZ |
|---|---|
| Sponsor | Novartis |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension (PHASE3)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension (PHASE4)
- Effect of Aliskiren and Hydrochlorothiazide on Kidney Oxygenation in Patients With Hypertension (PHASE4)
- Aldosterone and the Metabolic Syndrome (PHASE1)
- Treatment of Supine Hypertension in Autonomic Failure (PHASE1)
- Evaluating the Effect of Aliskiren Versus HCTZ on Coronary Flow Reserve in Hypertensive Type II Diabetics (PHASE4)
- The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aliskiren and HCTZ CI brief — competitive landscape report
- Aliskiren and HCTZ updates RSS · CI watch RSS
- Novartis portfolio CI
Frequently asked questions about Aliskiren and HCTZ
What is Aliskiren and HCTZ?
Who makes Aliskiren and HCTZ?
What development phase is Aliskiren and HCTZ in?
Related
- Manufacturer: Novartis — full pipeline
- Compare: Aliskiren and HCTZ vs similar drugs
- Pricing: Aliskiren and HCTZ cost, discount & access